Internistische Risikofaktoren bei der implantatprothetischen Behandlung

Der Leser soll nach Durcharbeiten des Beitrags

• über die Behandlungsrisiken bei kardiovaskulären Erkrankungen informiert sein,

• den Einfluss verschiedener Medikationen auf das Erreichen und die Stabilität der Osseointegration kennen,

• absolute Kontraindikationen für die Implantattherapie kennen.

Literatur

• 1 Alawi F.. Benign fibro–osseous diseases of the maxillofacial bones. A review and differential diagnosis.  Am J Clin Pathol. 2002;  188
• 2 Cranney A, Adachi JD.. Corticosteroid–induced osteoporosis: a guide to optimum management.  Treat Endocrinol. 2002;  1 271-279
• 3 Degidi M, Piattelli A.. Immediately loaded bar–connected implants with an anodized surface inserted in the anterior mandible in a patient treated with diphosphonates for osteoporosis: a case report with a 12–month follow–up.  Clin Implant Dent Relat Res. 2003;  5 269-272
• 4 Edwards BJ, Migliorati CA.. Osteoporosis and its implications for dental patients.  J Am Dent Assoc. 2008;  139 625-546
• 5 Grant BT, Amenedo C, Freeman K. et al. . Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases.  J Oral Maxillofac Surg. 2008;  66 223-230
• 6 Grines CL, Bonow RO, Casey Jr DE. et al. . Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians.  Catheter Cardiovasc Interv. 2007;  69 334-340
• 7 Grötz K, Kreusch T.. Zahnärztliche Betreuung von Patienten unter/nach Bisphosphonat–Medikation. DZZ 2006; 10: Stellungnahme der DGZMK V1.0 Stand 10/. 2006
• 8 Holahan CM, Koka S, Kennel KA. et al. . Effect of osteoporotic status on the survival of titanium dental implants.  Int J Oral Maxillofac Implants. 2008;  23 905-910
• 9 Jeffcoat MK.. Safety of oral bisphosphonates: controlled studies on alveolar bone.  Int J Oral Maxillofac Implants. 2006;  21 349-353
• 10 Jowett NI, Cabot LB.. Patients with cardiac disease: considerations for the dental practitioner.  Br Dent J. 2000;  189 297-302
• 11 Kalpidis CD, Konstantinidis AB.. Critical hemorrhage in the floor of the mouth during implant placement in the first mandibular premolar position: a case report.  Implant Dent. 2005;  14 117-124
• 12 Keats AS.. The ASA classification of physical status––a recapitulation.  Anesthesiology. 1978;  49 233-236
• 13 Khan AA, Sandor GK, Dore E. et al. . Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.  J Rheumatol. 2008;  35 1391-1397
• 14 Landesberg R, Eisig S, Fennoy I. et al. . Alternative indications for bisphosphonate therapy.  J Oral Maxillofac Surg. 2009;  67 27-34
• 15 Manzke E, Gruber H, Baylink D. et al. . Unterschiedliche rontgenologische, histomorphometrische und biochemische Befunde bei zwei Erwachsenen mit Osteopetrose.  Radiologe. 1982;  22 175-180
• 16 Marx RE.. Reconstruction of defects caused by bisphosphonate–induced osteonecrosis of the jaws.  J Oral Maxillofac Surg. 2009;  67 107-119
• 17 Marx RE, Cillo Jr JE, Ulloa JJ.. Oral bisphosphonate–induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.  J Oral Maxillofac Surg. 2007;  65 2397-2410
• 18 Marx RE, Sawatari Y, Fortin M. et al. . Bisphosphonate–induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.  J Oral Maxillofac Surg. 2005;  63 1567-1575
• 19 Morris HF, Ochi S, Winkler S.. Implant survival in patients with type 2 diabetes: placement to 36 months.  Ann Periodontol. 2000;  5 157-165
• 20 Mulligan R, Sobel S.. Osteoporosis: diagnostic testing, interpretation, and correlations with oral health––implications for dentistry.  Dent Clin North Am. 2005;  49 463-484
• 21 Rohlfing CL, Wiedmeyer HM, Little RR. et al. . Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial.  Diabetes Care. 2002;  25 275-278
• 22 Roper K.. Zur Klinik der Ostitis deformans Paget.  Med Klin. 1952;  47 799-802
• 23 Scheer M, Breuer K, Neugebauer J. et al. . Behandlung gerinnungsgestörter Patienten in der zahnärztlichen Praxis.  ZM. 2006;  96 38-44
• 24 Seymour RA.. Dentistry and the medically compromised patient.  Surgeon. 2003;  1 207-214
• 25 Tsolaki IN, Madianos PN, Vrotsos JA.. Outcomes of Dental Implants in Osteoporotic Patients. A Literature Review. J Prosthodont 2009
• 26 Wilde JT, Cook RJ.. von Willebrand disease and its management in oral and maxillofacial surgery.  Br J Oral Maxillofac Surg. 1998;  36 112-118

Korrespondenzadresse